17 Recruiting Chronic Lymphocytic Leukemia Phase 1 Clinical Trials
Active phase 1 studies for chronic lymphocytic leukemia enrolling across the USA. Verify eligibility and contact site coordinators.
All Chronic Lymphocytic Leukemia studiesPhase 1 Studies for Chronic Lymphocytic Leukemia
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
📍 Beth Isreal Deaconess Medical Center — Boston, Massachusetts
View Study & Checklist ➔Safe Accelerated Venetoclax Escalation in CLL
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
View Study & Checklist ➔Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
📍 Icahn School of Medicine at Mount Sinai — New York, New York
View Study & Checklist ➔Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
📍 Research Site — Boston, Massachusetts
View Study & Checklist ➔Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
📍 UC San Diego Moores Cancer Center — La Jolla, California
View Study & Checklist ➔huCART19-IL18 in CD19+ Cancers
📍 University of Pennsylvania — Philadelphia, Pennsylvania
View Study & Checklist ➔A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
📍 City of Hope /ID# 253904 — Duarte, California
View Study & Checklist ➔Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
📍 Research Site — Columbus, Ohio
View Study & Checklist ➔Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
📍 University of Miami- Sylvester Comprehensive Cancer Center — Miami, Florida
View Study & Checklist ➔Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
📍 University of California LA — Los Angeles, California
View Study & Checklist ➔A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
📍 OHSU Knight Cancer Institute — Portland, Oregon
View Study & Checklist ➔